Immune checkpoint inhibitors 1 result in impressive clinical responses [2] [3] [4] [5] , but optimal results will require combination with each other 6 and other therapies. This raises fundamental questions about mechanisms of non-redundancy and resistance. Here we report major tumour regressions in a subset of patients with metastatic melanoma treated with an anti-CTLA4 antibody (anti-CTLA4) and radiation, and reproduced this effect in mouse models. Although combined treatment improved responses in irradiated and unirradiated tumours, resistance was common. Unbiased analyses of mice revealed that resistance was due to upregulation of PD-L1 on melanoma cells and associated with T-cell exhaustion. Accordingly, optimal response in melanoma and other cancer types requires radiation, anti-CTLA4 and anti-PD-L1/PD-1. Anti-CTLA4 predominantly inhibits T-regulatory cells (T reg cells), thereby increasing the CD8 T-cell to T reg (CD8/T reg ) ratio. Radiation enhances the diversity of the T-cell receptor (TCR) repertoire of intratumoral T cells. Together, anti-CTLA4 promotes expansion of T cells, while radiation shapes the TCR repertoire of the expanded peripheral clones. Addition of PD-L1 blockade reverses T-cell exhaustion to mitigate depression in the CD8/T reg ratio and further encourages oligoclonal T-cell expansion. Similarly to results from mice, patients on our clinical trial with melanoma showing high PD-L1 did not respond to radiation plus anti-CTLA4, demonstrated persistent T-cell exhaustion, and rapidly progressed. Thus, PD-L1 on melanoma cells allows tumours to escape anti-CTLA4-based therapy, and the combination of radiation, anti-CTLA4 and anti-PD-L1 promotes response and immunity through distinct mechanisms.
Anecdotal clinical reports suggest that radiation may cooperate with anti-CTLA4 to systemically enhance melanoma response 7 ; however, this combination has not been reported in a clinical trial. To examine the feasibility and efficacy of radiation combined with immune checkpoint blockade, we initiated a phase I clinical trial of 22 patients with multiple melanoma metastases (Extended Data Table 1 ). A single index lesion was irradiated with hypofractionated radiation, delivered over two or three fractions, followed by four cycles of the anti-CTLA4 antibody ipilimumab (Extended Data Fig. 1a ). Accrual was completed in three out of four radiation dose levels, and treatment was well tolerated (Extended Data Table 2 ). Evaluation of the unirradiated lesions by computed tomography (CT) imaging using response evaluation criteria in solid tumours (RECIST) demonstrated that 18% of patients had a partial response as best response, 18% had stable disease, and 64% had progressive disease (Fig. 1a ). For example, patient PT-402 showed a large reduction in sizes of unirradiated tumours and a partial metabolic response by positron emission tomography (PET) (Fig. 1b ). None of the 12 patients evaluated by PET had progressive metabolic disease in the irradiated lesion (Extended Data Fig. 1b , Extended Data Table 3 ). The median progression-free survival and overall survival was 3.8 and 10.7 months with median follow-up of 18.4 and 21.3 months (18.0 and 21.3 for patients without event), respectively ( Fig. 1c) .
Although responses were observed, the majority of patients in our trial did not respond. To understand the contribution of radiation to immune checkpoint blockade and to discover mechanisms of resistance, we used the B16-F10 melanoma mouse model. Mice with bilateral flank tumours received anti-CTLA4, irradiation of one tumour (index) using a micro-irradiator, or both treatments delivered concurrently (Fig. 1d ). The best responses in both tumours occurred with radiation 1 anti-CTLA4. Radiation given before or concurrently with CTLA4 blockade yielded similar results (Extended Data Fig. 1c ). Complete responses were CD8 T-cell-dependent, and mice with complete responses also exhibited CD8 T-cell-dependent immunity to tumour re-challenge (Extended Data Fig. 1d-e ). However, similar to our clinical trial, only approximately 17% of mice responded. To better understand determinants of response, we derived cell lines from unirradiated tumours that relapsed after radiation 1 anti-CTLA4 (Res 499 and Res 177). Resistance was confirmed in vivo and was not due to intrinsic radiation resistance (Extended Data Fig. 2a -c). Random forest machine learning analysis 8, 9 of tumourinfiltrating lymphocytes (TILs) demonstrated that the top predictor of resistance, as measured by variable importance scores and selection, was the CD8 1 CD44 1 to T reg (CD8/T reg ) ratio ( Fig. 1e , Extended Data Fig. 2d ). In resistant tumours, the CD8/T reg ratio failed to increase after radiation 1 anti-CTLA4 as it did in sensitive tumours because CD8 1 CD44 1 T cells did not significantly expand despite reduction in T reg cells (Fig. 1f ). Other immune variables associated with resistance were also related to the failure to accumulate CD8 TILs.
The prevalence of CD8 TILs can be blunted by mechanisms that interfere with T-cell function. Transcriptomic profiling of Res 499/177 tumours revealed that PD-L1 was among the top 0.2% of upregulated genes that make up a radiation 1 anti-CTLA4 'resistance gene signature' (Extended Data Fig. 2e , Supplementary Table 1 ). Other genes include interferon-stimulated genes, which may promote immune suppression through PD-L1 10, 11 . Similarly, PD-L1 was co-expressed with the resistance signature in tumours from a previously reported 12 cohort of metastatic melanoma patients (Fig. 1g ). This increase in PD-L1 was observed on melanoma cells devoid of contaminating stromal cells, and a comparable increase was similarly seen in the Res 237 murine breast cancer cell line (Fig. 1h ), which was selected from the TSA line for resistance to radiation 1 anti-CTLA4 (Extended Data Fig. 2f, g) . In contrast, expression of other inhibitory receptors and their ligands nominated by gene profiling did not suggest an obvious role in resistance (Extended Data Fig. 2h , i). Indeed, genetic elimination of PD-L1 on Res 499 cells by CRISPR (Extended Data Fig. 2j ) restored response to radiation 1 anti-CTLA4 by increasing survival from 0% to 60% ( Fig. 1i ). Thus, an increase in PD-L1 on tumour cells observed in multiple cancer types can be a dominant resistance mechanism to radiation 1 anti-CTLA4.
Elevated levels of PD-L1 can promote T-cell exhaustion, a state characterized by dysfunction in T-cell proliferation and effector function 13 . Exhausted T cells co-express the PD-L1 receptor PD-1 and the unirradiated tumours and is inhibited by PD-L1 on tumour cells. a, Waterfall plot of unirradiated tumours after radiation treatment (RT) to a single index lesion with anti-CTLA4. Dashed lines are thresholds for progressive disease (PD; red) and partial response (PR; blue). *Patients with new lesions. **Clinical progression without imaging. 95CI, 95% confidence interval. b, PET/CT images of irradiated (white arrows) and unirradiated (yellow arrows) tumours from patient PT-402. c, Progression-free survival (PFS) and overall survival (OS) for all patients (dashed lines, 95CI). d, B16-F10 tumour growth after RT to the index tumour (n 5 8), anti-CTLA4 (C4) (n 5 9), anti-CTLA4 and RT to the index tumour (n 5 18), or no (control) treatment (n 5 9). The P values are comparisons with control using a linear mixed-effects model. Pie chart shows per cent complete responses (yellow). See Fig. 2d for survival. e, Heat map showing relative abundance of immune cells or their ratios from tumours that are resistant (black hatch) or sensitive to RT 1 anti-CTLA4. Boxplot shows bootstrap importance scores for each variable. Higher values (red) are more predictive. f, Change in T cell subsets or their ratio after RT 1 anti-CTLA4 for sensitive parental (Sen) or resistant (Res) tumours. Values are subtracted from average of untreated controls. Red line is mean. g, Heat map of resistance gene signature and PD-L1 across human melanoma. P , 0.001 by gene set enrichment analysis. h, Expression of PD-L1 on Res 499 compared to B16-F10 melanoma cells and of Res 237 compared to TSA breast cancer cells. Isotype control (IgG). i, Total tumour volume from PD-L1 knockout (KO) or control (WT) Res 499 and corresponding survival. Two-tailed t-test or Wilcoxon test was used for two-way comparisons of biological replicates. Log-rank test was used for survival analysis. transcription factor Eomes 14 . Reversal of exhaustion, known as reinvigoration, is marked by an increase in the proliferation marker Ki67 and the cytotoxic protein GzmB within the exhausted T-cell pool. In both untreated parental and resistant tumours, approximately 20% of CD8 TILs co-expressed PD-1 and Eomes, and only a minority of these cells were Ki67 1 GzmB 1 , indicating that a significant fraction was exhausted ( Fig. 2a, b ). In B16-F10 tumours, radiation 1 anti-CTLA4 markedly increased both the proportion of PD-1 1 Eomes 1 CD8 T cells and the proportion that were Ki67 1 GzmB 1 within this subset. In contrast, in resistant tumours the average proportion of PD-1 1 Eomes 1 T cells that were Ki67 1 GzmB 1 only marginally increased after radiation 1 anti-CTLA4; however, addition of anti-PD-L1 increased this to levels observed in parental tumours treated with only radiation 1 anti-CTLA4. The frequency of CD8 1 CD44 1 TILs and the CD8/T reg ratio also increased ( Fig. 2c ), and these were strongly correlated with the proportion of PD-1 1 Eomes 1 CD8 TILs that were Ki67 1 GzmB 1 (Extended Data Fig. 3a) . Importantly, addition of anti-PD-L1 improved responses of resistant Res 499 tumours after radiation 1 anti-CTLA4 (Extended Data Fig. 3b, c) . For treatment-naive tumours, responses were even more notable as the addition of either anti-PD-L1 or anti-PD-1 to radiation 1 anti-CTLA4 markedly improved survival and increased complete responses to 80% ( Fig. 2d , Extended Data Fig. 3d-f ). On average, 58% of mice with complete responses after adding anti-PD-L1 or anti-PD-1 were alive 901 days after tumour rechallenge, and similar improvements were observed with Res 237 breast cancer tumours after addition of PD-L1 blockade (Extended Data Fig. 3g -i). Thus, elevated PD-L1 on tumour cells results in persistent T-cell exhaustion that impairs the CD8/T reg ratio. Addition of PD-L1 blockade inhibits resistance and results in long-term immunity.
Notably, radiation is needed to achieve high complete response rates as dual checkpoint blockade proved inferior to dual checkpoint blockade plus radiation ( Fig. 2d ), a requirement additionally seen in a pancreatic cancer model (Extended Data Fig. 3j ). The superiority of triple therapy in multiple cancer types suggests non-redundant mechanisms for each treatment. To examine this notion, we assessed treatment-related changes in TILs from unirradiated tumours. Random forest modelling of immune cell profiles confirmed that anti-CTLA4 predominantly caused a decrease in T reg cells, anti-PD-L1 strongly increased CD8 TIL frequency, and the blockade of both increased the CD8/T reg ratio ( Fig. 3a , b, Extended Data Fig. 4a ). In contrast, radiation caused only a modest increase in CD8 TILs; however, TCR sequencing revealed that this was accompanied by increased diversity of TCR clonotypes, which could be observed even in the presence of CTLA4 blockade ( Fig. 3c, d) . Thus, within the tumour microenvironment, CTLA4 blockade primarily decreases T reg cells, PD-L1 blockade predominantly reinvigorates exhausted CD8 TILs, and radiation diversifies the TCR repertoire of TILs from unirradiated tumours.
To investigate if treatment effects on TILs were propagated to the peripheral T-cell pool, we examined spleen and blood. As observed in TILs, radiation 1 anti-CTLA4 reinvigorated exhausted PD-1 1 Eomes 1 splenic CD8 T cells, and this reinvigoration was further enhanced by 
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addition of anti-PD-L1 ( Fig. 3e, f) . Reinvigoration after addition of anti-PD-L1 was also accompanied by a large expansion of a small subset of the top 100 most frequent TCR clonotypes found in TILs ( Fig. 3g ).
Remarkably, some clones reached a frequency in the post-treatment blood of over 20% after radiation and dual checkpoint blockade ( Fig. 3h ). With anti-CTLA4 6 radiation, peripheral T cell clonal expansion was modest, which parallels the low complete response rates following this treatment. Radiation alone was insufficient to drive peripheral T-cell expansion, despite increasing TCR repertoire diversity of TILs, but did promote qualitative alterations in the TCR repertoire of the most expanded clonotypes. Unsupervised analysis using the average CDR3 amino acid features 15, 16 demonstrated that the TCRs of the most frequent clonotypes in the post-treatment blood formed two readily apparent clusters on the basis of radiation treatment (Fig. 3i ). In contrast, the most frequent clonotypes from pre-treatment blood and randomly sampled clonotypes from post-treatment blood did not separate into clusters, consistent with differences in CDR3 amino acid properties being an effect of radiation only observed in the most expanded clones (Extended Data Fig. 4b, c ). The separation into two clusters was driven by differences in the CDR3 occupancy profile of short amino acid sequences belonging to distinct subsets differing in size, polarity, and electrostatic charge (Extended Data Fig. 4d, e ). Together, these observations suggest that the favourable immune changes in TILs after immune checkpoint blockade promote their peripheral clonal expansion. When combined with increased TCR repertoire diversity afforded by radiation, selection and oligoclonal peripheral expansion of clones with distinct TCR traits are favoured.
To determine if treatment and resistance-related changes in peripheral T cells can constitute a biomarker for tumour response, we modelled the effects of reinvigoration, exhaustion, and the CD8/T reg ratio. Specifically, we used (1) the percentage of PD-1 1 splenic CD8 T cells that are Eomes 1 to integrate the burden that exhausted T cells might exert, (2) the percentage of PD-1 1 CD8 T cells that are Ki67 1 GzmB 1 as a measure of potential reinvigoration, and (3) the CD8/T reg ratio as a barometer for the suppressive potential of T reg cells. The overall prediction accuracy of the model was 84%, and variables for T-cell reinvigoration and exhaustion were the most predictive, followed by the CD8/T reg ratio (Extended Data Fig. 5a, b ). Moreover, the percentage of PD-1 1 CD8 T cells that were Eomes 1 was a striking modifier of the likelihood of complete response as nearly all observed complete responses occurred when the percentage of Ki67 1 GzmB 1 in PD-1 1 CD8 T cells was high but the relative size of the PD-1 1 Eomes 1 exhausted population was small ( Fig. 4a ). Similar relationships existed with the CD8/T reg ratio, and prediction using T cells from peripheral blood yielded highly similar results (Extended Data Fig. 5c-e ). In total, immune parameters from peripheral T cells that relate the size of the exhausted T-cell population, reinvigoration, and the CD8/T reg ratio can predict response to radiation combined with immune checkpoint blockade.
To assess whether immune predictors discovered in mice could be shared with patients, we examined peripheral T cells and tumour biopsies from patients on our clinical trial of radiation 1 anti-CTLA4. For all 10 patients with available pre-and post-treatment blood, two had partial responses in unirradiated tumours and progression-free survival significantly longer than the median. For both of these patients, the percentages of Ki67 1 GzmB 1 increased in PD-1 1 Eomes 1 CD8 T cells after treatment while the proportion of PD-1 1 Eomes 1 T cells remained at or below the mean (Fig. 4b) . In contrast, patients with a high percentage of PD-1 1 Eomes 1 T cells post-treatment did not have partial responses and had a short progression-free survival, regardless of reinvigoration. Comparison of patient PT-402, who had extended progression-free survival/partial response ( Fig. 1a, b) , with patient PT-102, who had short progression-free survival/progressive disease, demonstrates how reinvigoration is associated with response to radiation 1 anti-CTLA4 as it is in mice ( Fig. 4c vs Fig. 3e , f and Extended Data Fig. 5f, g) . Examination of pre-treatment tumour biopsies from patients PT-402 and PT-102 ( Fig. 4d) , and from all patients with available biopsy (Extended Data Table 4 ), revealed that PD-L1 lo intensity on melanoma cells (Extended Data Fig. 6a ) was associated with reinvigoration of PD-1 1 Eomes 1 and of PD-1 1 CD8 T cells after radiation 1 anti-CTLA4, while PD-L1 hi status was associated with persistent exhaustion (Fig. 4e , Extended Data Fig. 6b ). None of the patients with PD-L1 hi on melanoma cells had a complete response/partial response, and all rapidly progressed and died ( Fig. 4f, g) . PD-L1 status on macrophages was neither associated with reinvigoration nor independently predictive of progressionfree survival (Extended Data Fig. 6c, d ). Thus, collective results from patients and mice suggest that elevated PD-L1 on melanoma cells inhibits T-cell function and tumour response to radiation 1 anti-CTLA4.
We investigated radiation 1 anti-CTLA4 in mice and patients to understand mechanisms of both response and resistance (Extended Data Fig. 6e ). Anti-CTLA4 predominantly inhibits T reg cells, increasing the 
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CD8/T reg ratio as previously described 17 , and results in modest peripheral expansion of TCR clonotypes in the tumour, also consistent with other reports 18, 19 . Radiation diversifies the TCR repertoire of TILs and shapes the repertoire of expanded clones. Although the cause and consequence of these repertoire changes remain to be defined, radiation can alter peptide presentation 20 , and CDR3 changes after Mycobacterium tuberculosis infection have been hypothesized to be antigen-driven 15 .
Resistance to radiation 1 anti-CTLA4 can ensue due to elevated PD-L1 on cancer cells driving T-cell exhaustion, a process that can be antagonized by PD-L1 blockade. However, severely exhausted T cells may regain only limited function after reinvigoration 13, 14 , explaining why the correlation between reinvigoration and response declines when the exhausted T-cell pool is large. Although tumours with genetic elimination of PD-L1 in melanoma cells can still relapse, suggesting resistance through other pathways and/or PD-L1 on non-tumour cells, the upregulation of PD-L1 by cancer cells is a dominant resistance mechanism in our models. Moreover, the shared findings between mice and patients predict that addition of PD-L1/PD-1 blockade to radiation 1 anti-CTLA4 may show significant efficacy in clinical trials. 
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METHODS
Clinical trial patients and study design. The clinical protocol was registered on http://clinicaltrials.gov (NCT01497808). Eligible patients were at least 18 years of age with previously treated or untreated stage IV melanoma with multiple metastasis. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1, adequate renal, hepatic, and haematological function, no current or history of CNS metastasis, no prior radiation that precludes use of stereotactic body radiation (SBRT), and at least one tumour between 1 and 5 cm that could be treated with SBRT. The primary objectives of this phase I study were to determine feasibility, dose-limiting toxicities (DLT) and maximum tolerated SBRT fraction when given in conjunction with ipilimumab. The secondary objectives were to determine late toxicity, immune-related clinical responses and changes.
The study treated successive cohorts of patients with escalating doses of SBRT to a single tumour (index lesion), followed 3-5 days later by ipilimumab every three weeks for four doses. Moderate radiation doses were used since higher radiation dose has not been clearly correlated with better immune response but would be likely to increase toxicity. Patients were stratified into two strata based on treatment site (lung or bone vs liver or subcutaneous) and dose escalation of SBRT was determined as follows: For lung/bone lesion, dose level 1 (DL1) was 8 Gy 3 2; dose level 2 (DL2) was 8 Gy 3 3; and for liver/subcutaneous lesion, DL1 was 6 Gy 3 2; DL2 was 6 Gy 3 3. The study followed a ''treat six'' design with the goal of accruing 6 patients to each dose level, or 24 patients total. Enrolment to a dose level would stop if 2 or more patients had a DLT. If 0-1 patients out of the 6 had a DLT at DL1, escalation to DL2 would proceed. There were no observed DLTs, defined by the protocol as any treatment-related grade 4 or higher immune-related toxicity (NCI CTC Version 4.0) or grade 3 or higher non-immune related toxicity experienced during study treatment or within 30 days after the last injection of ipilimumab. Preand post-treatment blood, CT, and PET/CT scans were obtained to follow tumour response and assess immune responses. Response evaluation by imaging was performed within 60 days of the last ipilimumab treatment using either RECIST v1.1 21 or PERCIST. The study protocol was approved by the University of Pennsylvania institutional review board. All participating patients provided written informed consent.
Cell lines and tissue culture. B16-F10 was purchased from ATCC. TSA was a gift from Sandra Demaria. PDA.4662 cell line was derived from single-cell suspensions of PDA tissue from Kras LSL-G12D/1 , p53 LSL-R172H/1 ,Pdx1-Cre mice as previously described 22 . B16-F10 and PDA.4662 cell lines were cultured at 37 uC in DMEM and TSA cells were cultured at 37 uC in RPMI. Media was supplemented with 10% FBS, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin, 2 mM L-glutamine. All cell lines were determined to be free of Mycoplasma (Lonza) and common mouse pathogens (IDEXX).
In vivo mouse studies. Five to seven week old female C57BL/6 and BALB/c mice were obtained from NCI Production (Frederick, MD) and Jackson Laboratory (Bar Harbour, ME) and maintained under pathogen-free conditions. All animal experiments were performed according to protocols approved by the Institute of Animal Care and Use Committee of the University of Pennsylvania. For B16-F10 melanoma, 5 3 10 4 B16-F10 cells were mixed with an equal volume of Matrigel (BD Biosciences) and subcutaneously injected on the right flank of C57BL/6 mice on day 0 and the left flank on day 2. The right flank tumour site was irradiated with 20 Gy on day 8. Blocking antibodies were given on days 5, 8 and 11. For the concurrent vs sequential radiation experiment, the right flank was irradiated on either day 8 (sequential) or 12 (concurrent), while blocking antibodies were given on days 9, 12, and 15. For TSA breast cancer, 1 3 10 5 TSA cells were mixed with an equal volume of Matrigel (BD Biosciences) and subcutaneously injected on the right flank of BALB/c mice on day 0 and the left flank on day 2. The right flank was irradiated with 8 Gy on three consecutive days starting on day 10 or 11 post tumour implantation. Blocking antibodies were started 3 days before radiation and given every 3 days for a total of 3 doses. For the pancreatic cancer model, 4 3 10 5 PDA.4662 cells were subcutaneously injected on the right flank. The right flank was irradiated with 20 Gy on day 8. Blocking antibodies were given on days 5, 8, and 11. For melanoma and breast cancer models, we used the optimal dose and fraction of radiation as previously reported 23,24 . All irradiation was performed using the Small Animal Radiation Research Platform (SARRP). Antibodies used for in vivo immune checkpoint blockade experiments were given intraperitoneally at a dose of 200 mg per mouse and include: CTLA4 (9H10), PD-1 (RMP1-14), PD-L1 (10F.9G2), CD8 (2.43), and rat IgG2B isotype (LTF-2) (BioXCell). Anti-CD8 was given 2 days before tumour implantations (day 22), day 0, then every 4 days for the duration of the experiment. Perpendicular tumour diameters were measured using calipers. Volume was calculated using the formula L 3 W 2 3 0.52, where L is the longest dimension and W is the perpendicular dimension. Survival and tumour response analysis. Differences in survival were determined for each group by the Kaplan-Meier method and the overall P value was calculated by the log-rank test using the ''survival'' R package version 2.371. For mouse studies, an event was defined as death or when tumour burden reached a protocol-specified size of 1.5 cm in maximum dimension to minimize morbidity. To help control for differences in treatment response due to experimental variation or intrinsic growth differences with sublines, tumour volume measurements were also analysed after normalizing to the average volumes of untreated control mice. These average untreated tumour volumes were determined at day 11-12, a time when tumour dimensions could be accurately measured, and was considered a baseline tumour volume (V cont ). Normalized tumour response to treatment is the measured volume (V) relative to V cont , or V/V cont , a dimensionless value. Measurements from different experiments separated by 1-2 days were binned. Differences in growth curves were determined by a linear mixed-effects model with normalized data using the ''lmerTest'' R package version 2.0. Sample size estimations were based on preliminary pilot experiments. For control mice, we expected an average tumour volume of 0.4 cm 3 at day 17-21. For most experiments, we assumed the treatment group would have an effect size resulting in a 50% reduction in average tumour volume. Sigma was estimated to be 1.5. For a 0.80 power at the 0.05 alpha level, this gave us a sample size of 5 mice. Mice were randomly assigned a treatment group. For experiments whereby the effect size was expected to be small and/or non-robust, two independent researchers with at least one researcher blinded to the treatment group assignments performed caliper measurements. Immunohistochemistry for PD-L1. Formalin-fixed, paraffin-embedded tumours were collected at the time of surgical resection or from biopsy. All patients with available recent biopsy, which was optional for trial enrolment, were used for analysis. After heat-induced antigen retrieval (Bond ER2, 20 min.), the tumour slides were stained with an anti-PD-L1 antibody (E1L3N, Cell Signaling) at 1:50 dilution. Intensity of staining on a 0-31 scale, the percentage of tumour cells or macrophages with positive staining, and the cellular pattern (membrane vs cytoplasm) were analysed by two pathologists. Samples with membrane PD-L1 staining intensity score of 0-1 were classified as PD-L1 lo , and samples with an intensity score of 21 in at least 1% of the cells were classified as PD-L1 hi . To confirm specificity, the anti-PD-L1 antibody was validated by staining Hodgkin's lymphoma cells 25 and placenta 26 
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common to the 1.0 and 2.0 ST arrays were kept. Batch effects were adjusted using the ComBat method as implemented in the ''sva'' R package version 3.8.0. The microarray data has been deposited at the GEO (GSE65503) and processed data provided as Supplementary Table 2 . Gene expression data for primary melanoma samples were downloaded from the GEO (GSE22155). For this data set, the postprocessed data and provided annotations were used. Determining differentially expressed genes and enriched gene sets. Non-specific filtering was used to remove genes with an interquartile range less than 0.05. To find differentially expressed genes between parental sensitive and resistant tumours, Significance Analysis of Microarray 28 (''samr'' R package version 2.0) was applied using a two class unpaired comparison, minimal Z-score fold change of 1.2, and median false discovery rate of 0.05. Unannotated transcripts were not considered. To test whether gene sets were enriched in response to different conditions, we used Gene Set Analysis as implemented in the ''GSA'' R package version 1.03 29 . The ''maxmean'' test statistic was used to test enrichment using a two-class comparison. All P values and false discovery rates were based on 500-1,000 permutations. For restandardization, a method that combines randomization and permutation to correct permutation values of the test statistic and to take into account the overall distribution of individual test statistics, the entire data set was used rather than only the genes in the gene sets tested. Flow cytometry data processing. Gating was performed using either FlowJo version 9.7.5 or the FlowCore R package version 1.28.24. For computational modelling, values were normalized by subtracting the average values of untreated controls. For the CD8/T reg ratio, the percentage of CD8 1 CD44 1 cells were divided by the percentage of CD4 1 FOXP3 1 cells. Because these data could be skewed with varying and wide distributions, these data were log-transformed for downstream analysis.
Random forest for classification and survival analysis. Random forest for classification, regression, and survival analysis is a multivariable non-parametric ensemble partitioning tree method that can be used to model the effect of all interactions between genes on a response variable 30,31 . Each model was constructed using approximately two-thirds of randomly selected samples and cross-validated on the onethird of the samples left out of the model building process (out-of-bag samples). After many iterations, results of all models were averaged to provide unbiased estimates of predicted values, error rates, and measures of variable importance. Performance of a random forest model was measured by the misclassification error rate for classification, mean squared error for regression, and by a concordance index (one minus the error rate) for survival. For each variable, an importance score was determined, which measures the contribution of the variable to the error rate (higher scores are more predictive). When multiple response variables were modelled, as in the case of determining which treatment predicts changes in a set of immune parameters, treatment groups were converted to a design matrix and importance scores were determined for each response variable. We used the ''randomForestSRCM'' R package version 1.2 implementation 32 and the following parameters: 1,000 trees, node size of 1, mtry values equal to the number of variables in the model, and the Breiman-Cutler permutation method for importance score determination 9 . Gini index splitting rule was used for classification and a log-rank slitting rule was used for survival analysis. For classification, stratified sampling was used when the number of samples in each class was imbalanced. All predicted values, error rates, and importance scores were calculated using out-of-bag samples to provide unbiased estimates. To account for variance due to sample size and sampling error on the accuracy of these performance measures, bootstrapping was performed using 1,000-5,000 bootstrap iterations and the mean and standard deviation of the bootstrap distribution were determined. For presentation purposes, cut-off values for predictive variables were determined by using partial plots to estimate inflection points. Minimal depth was used as a rigorous method to select predictive variables. Minimal depth (MD) is a dimensionless statistic that we have recently described 8 that measures the predictiveness of a variable in tree-based models. Specifically, MD measures the shortest distance from the root node of a classification/regression tree to the parent node of a maximal subtree for a variable. The maximal subtree for a variable is the largest subtree whose root node splits on the variable. Thus, smaller values for MD indicate better predictiveness. A threshold value for MD that is calculated from the tree-averaged value determines whether a variable is strongly predictive. The entire MD-based variable selection is performed using two-third of the samples (in-bag samples). An unbiased prediction error rate for a model refit with the MD-selected variables is calculated using only out-of-bag samples. Using the ''randomForestSRCM'' package, we applied this MD-based variable selection with the same parameters used for random forest as noted above. The tree-averaged MD threshold was used. Data were bootstrapped to provide robust estimates of MD values and prediction error rates. The frequency of bootstrap models whereby the MD values for a variable was less than the MD threshold determined how often a variable was selected as a top variable, which provides an estimate for the stability of variable selection.
TCR deep sequencing and clonotype diversity analysis. DNA from pre-treatment blood, post-treatment blood, and tumour was extracted on day 16 using the Qiagen DNA extraction protocol. Samples were sequenced by Adaptive Biotechnologies using ''survey'' sequencing depth for tumour and ''deep'' sequencing depth for blood samples. Processed data were downloaded and frequencies/counts for TCR clonotypes were examined by nucleotide sequences after non-productive reads were filtered out. The top 100 most frequent TCR clonotypes in the tumour were used to examine their frequencies in the pre-and post-treatment blood. The Shannon's diversity index 33 (DI) normalized to the number of reads (DI 5 2 P (p i ln p i )/ln n, where n is the number of clones, p i is the clonal frequency of the ith clone, and sigma is summed from i 5 1 to i 5 n) was calculated for each sample. This gives a value between 0 and 1, where 0 is monoclonal and 1 is an even distribution of different clones. Unsupervised and supervised analysis of CDR3 amino acid properties. Based on previously described methods 15, 16 , Atchley factors were used to reduce a linear sequence of amino acids into analysable numeric features of distinct amino acid properties. The five Atchley factors and the attributes they measure are the following. (1) PAH: accessibility, polarity, and hydrophobicity; (2) PSS: propensity for secondary structure; (3) MS: molecular size; (4) CC: codon composition, (5) EC: electrostatic charge. Each CDR3 was represented as a set of all possible contiguous amino acids of length p (p-tuple). We chose p 5 3 based on previous published reports but examined a range of P values, which gave comparable results (see below). For each p-tuple, the Atchley factors for the amino acids were then calculated to give a vector of length 5p, or 15 (3 amino acids 3 5 Atchley factors). Thus, each CDR3 was represented by a set of these vectors. The average values for these vectors were calculated for the top B most frequent clones from the post-treatment blood. A cut-off of B 5 5 was chosen based on examination of the frequency distribution of the TCR clonotypes and an estimate of the number of clones with extreme values compared to the rest of the distribution. These averaged values were then clustered into two groups by k-means clustering with k 5 2. The association between cluster membership and treatment with or without radiation was calculated by Fisher's exact test. This entire process was repeated for the five clones in the pre-treatment blood, for randomly drawn clones from the post-treatment blood, for p-tuple lengths from p 5 2 to 10, and for cut-off values from B 5 3 to 50. In all cases, the distribution of P values was compared to the P value from the observed data.
Although averaging the Atchley factor values is a simple method to agglomerate CDR3 features for unsupervised classification, it does not provide insight into how treatment groups influence the amino acids that comprise the CDR3. To understand which sets of p-tuples were most strongly influenced by treatment groups with radiation, without radiation, and pre-treatment blood, we used previously described methods 15 to assign p-tuples into n clusters based on their Atchley factor vector. Model based clustering with cluster number determination using the ''mclust'' R package was applied to all p-tuples from the top five clones in all treatment groups from pre-and post-treatment blood. This gave rise to 17 clusters, or subsets, of p-tuples. The proportion of p-tuples belonging to each of these 17 subsets, denoted P i , was then calculated for each clonotype and used as features. The subsets that were most influenced by treatment group (treatment group with radiation, without radiation, or pre-treatment) were then analysed by multivariable random forest regression using a design matrix for treatment groups as the x-variable and P i as the response variable. The variables P i most affected by each treatment group were selected by comparing the observed importance scores to the importance scores generated by permutation. To determine the location and frequencies of amino acids belonging to the selected p-tuple subsets across the variable length CDR3 region, the CDR3 of each clone was divided into 10 bins of equal size. Then, the proportion of p-tuples in each of these 10 bins belonging to the selected subset was calculated and compared between treatment groups. The P values are for comparisons to RT 1 anti-CTLA4 (n 5 18, n 5 5 for others). Pie charts show % complete responses (yellow). e, Survival of mice after RT 1 anti-CTLA4 1 anti-PD-1. Shown is the overall P value, and f, the two-way comparisons that include those from Fig. 2d . g, Proportion of mice with complete responses (yellow) after RT 1 anti-PD-L1 or anti-PD-1 that survived 901 days after tumour rechallenge at day 60 (n 5 12 Response of the local irradiated site (Local) and distant unirradiated sites (Dist) were determined by CT and PET/CT. Percent change from baseline for distant lesions measured by CT are indicated using RECIST and change measured by PET/CT are indicated by PERCIST. The irradiated tumour was not included in RECIST measurements per RECIST guidelines due to radiation-related effects precluding accurate CT measurements (for example, patient ID 1 and 9). NA indicates the value was not measurable based on criteria. Progression of disease due to new lesion(s) before re-imaging (POD New) or due to clinical progression (POD Clin) is also indicated. PD, progression of disease; PR, partial response; SD, stable disease; CMR, complete metabolic response; PMR, partial metabolic response; PMD, progressive metabolic disease. Patient ID 3 is patient PT-102, and patient ID 4 is patient PT-402.
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